BDgene Completes $9 Million Round for CRISPR/Cas9 mRNA Candidates

Shanghai BDgene Technology completed a $9 million Series A round to develop its mRNA delivery platform, a viroid-like particle delivery system of mRNA. BDgene, a clinical stage company, uses the technology to deliver CRISPR/Cas9 mRNA, which provides safe and controllable gene editing in vivo, according to the company. BDgene's lead product is BD111, a CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy administered via corneal injection in patients with refractory herpetic viral keratitis, which has been approved for a six patient clinical trial in China. More details.... Share this with colleagues: // //